Back to top
more

Halozyme Therapeutics (HALO)

(Real Time Quote from BATS)

$59.26 USD

59.26
1,118,649

-3.05 (-4.90%)

Updated Sep 19, 2024 03:34 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (84 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Repligen's (RGEN) Q2 Earnings & Revenues Meet Estimates

Repligen's (RGEN) second-quarter earnings and revenues match estimates. The company narrows its revenue guidance for 2024. Stock rises.

United Therapeutics (UTHR) Q2 Earnings Lag, Sales Top Estimates

United Therapeutics (UTHR) reports mixed second-quarter 2024 results. Tyvaso sales continue to drive the company's top line.

Merck (MRK) Q2 Earnings & Sales Beat Estimates, Cuts '24 EPS View

Merck (MRK) posts better than expected second-quarter results, backed by strong demand for blockbuster cancer drug Keytruda. The stock falls in pre-market trading, likely due to the EPS guidance slash.

Corcept (CORT) Q2 Earnings & Revenues Surpass Estimates

Corcept (CORT) beats on both earnings and sales in the second quarter of 2024. The company increases revenue guidance for 2024.

Incyte's (INCY) Q2 Earnings Lag Estimates, Revenues Top

Incyte's (INCY) second-quarter 2024 earnings miss estimates while revenues beat the same. The company raises the bottom end of the 2024 revenue guidance for its lead drug, Jakafi.

Zacks Industry Outlook Highlights Moderna, Sarepta Therapeutics, Halozyme Therapeutics, Krystal Biotech and Axsome Therapeutics

Moderna, Sarepta Therapeutics, Halozyme Therapeutics, Krystal Biotech and Axsome Therapeutics have been highlighted in this Industry Outlook article.

Ekta Bagri headshot

5 Biotech Stocks to Bet On Bright Industry Prospects

New drug approvals and strong pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position MRNA, SRPT, HALO, KRYS and AXSM well in this volatile sector.

Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Rank.

Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks.com featured highlights include Amazon.com, Halozyme Therapeutics, Tenet Healthcare and Atmos Energy

Amazon.com, Halozyme Therapeutics, Tenet Healthcare and Atmos Energy are part of the Zacks Screen of the Week article.

Sumit Singh headshot

4 Stocks With Impressive Interest Coverage Ratio to Buy Now

A company capable of generating earnings well above its interest expense can withstand financial hardship. AMZN, HALO, THC and ATO are sound enough to meet financial obligations.

Kinjel Shah headshot

J&J (JNJ) Q2 Earnings & Sales Top, EPS View Cut on M&A Costs

J&J (JNJ) beats estimates for second-quarter earnings and sales. It lowers earnings expectations for 2024 due to costs related to recent acquisitions.

Select Medical's (SEM) Unit Begins IPO Roadshow for 22.5M Shares

Select Medical's (SEM) subsidiary, Concentra, starts roadshow for IPO of 22.5 million shares, aiming to list on the NYSE under ticker "CON" with an expected price range of $23-$26 per share.

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Shaun Pruitt headshot

Top Medical Stocks to Buy for Growth & Performance

The medical sector is crawling with opportunity as indicated in its representation on the Zacks Rank #1 (Strong Buy) list.

How to Find Strong Buy Medical Stocks Using the Zacks Rank

The Zacks Rank offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.

If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now

Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.

Is Halozyme Therapeutics (HALO) a Solid Growth Stock? 3 Reasons to Think "Yes"

Halozyme Therapeutics (HALO) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why Is Kodiak Sciences (KOD) Down 26.2% Since Last Earnings Report?

Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Allogene Therapeutics (ALLO) Down 13.9% Since Last Earnings Report: Can It Rebound?

Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.